INVO Fertility, Inc (NASDAQ:IVF) Sees Large Decrease in Short Interest

INVO Fertility, Inc (NASDAQ:IVF) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 26,478 shares, a decrease of 47.2% from the September 30th total of 50,118 shares. Based on an average trading volume of 140,470 shares, the short-interest ratio is presently 0.2 days. Currently, 1.1% of the shares of the company are short sold.

INVO Fertility Price Performance

NASDAQ:IVF traded down $0.08 during trading hours on Monday, reaching $1.83. 53,869 shares of the company were exchanged, compared to its average volume of 114,971. The business has a 50 day moving average of $13.26 and a 200 day moving average of $37.03. INVO Fertility has a 1-year low of $1.59 and a 1-year high of $98.00. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.71 and a quick ratio of 0.67. The company has a market capitalization of $4.59 million, a P/E ratio of -0.05 and a beta of 2.39.

INVO Fertility (NASDAQ:IVF) last announced its quarterly earnings data on Friday, August 14th. The company reported $5.60 earnings per share for the quarter. The firm had revenue of $2.18 million during the quarter. INVO Fertility had a negative return on equity of 85.54% and a negative net margin of 116.29%.

Analyst Ratings Changes

Several analysts have weighed in on IVF shares. Wall Street Zen upgraded shares of INVO Fertility to a “hold” rating in a research note on Saturday, August 29th. Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a research report on Friday. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $320.00.

About INVO Fertility

INVO Fertility, Inc is a commercial-stage fertility company focused on expanding access to assisted reproductive technology. The company develops and commercializes fertility products and services designed to provide alternatives to conventional in vitro fertilization (IVF) treatment.

Its principal product is INVOcell, a medical device used in the INVO Procedure. The system allows early-stage embryo incubation to take place inside the patient’s body rather than in a conventional laboratory incubator, while still involving the retrieval of eggs, fertilization, and subsequent embryo transfer under the supervision of fertility professionals.

In addition to commercializing INVOcell, INVO Fertility operates and supports fertility centers that provide reproductive services, including IVF and related treatments.